Janus Henderson Group PLC Has $907,000 Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Janus Henderson Group PLC cut its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 14.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 13,315 shares of the medical research company’s stock after selling 2,185 shares during the quarter. Janus Henderson Group PLC’s holdings in Exact Sciences were worth $907,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of EXAS. William Blair Investment Management LLC bought a new stake in shares of Exact Sciences in the second quarter valued at about $163,896,000. Sculptor Capital LP acquired a new position in shares of Exact Sciences during the 2nd quarter worth about $32,819,000. Samlyn Capital LLC bought a new stake in Exact Sciences in the second quarter valued at approximately $30,426,000. Armistice Capital LLC raised its stake in Exact Sciences by 91.6% in the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock valued at $59,154,000 after acquiring an additional 669,438 shares during the period. Finally, ArrowMark Colorado Holdings LLC acquired a new stake in shares of Exact Sciences during the 3rd quarter worth about $28,608,000. 88.82% of the stock is owned by institutional investors.

Insider Activity at Exact Sciences

In related news, CEO Kevin T. Conroy purchased 19,500 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This represents a 1.85 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This represents a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.36% of the stock is currently owned by company insiders.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $61.25 on Friday. The firm has a market capitalization of $11.34 billion, a price-to-earnings ratio of -52.35 and a beta of 1.24. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The business’s 50-day moving average price is $62.73 and its 200-day moving average price is $56.78. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company’s revenue was up 12.8% on a year-over-year basis. Equities research analysts forecast that Exact Sciences Co. will post -1.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on EXAS shares. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Wells Fargo & Company assumed coverage on shares of Exact Sciences in a report on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price objective for the company. BTIG Research increased their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus dropped their price target on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, TD Cowen increased their price target on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.94.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.